HomeCompareSYK vs CEQP

SYK vs CEQP: Dividend Comparison 2026

SYK yields 1.04% · CEQP yields 9.27%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CEQP wins by $130.5K in total portfolio value
10 years
SYK
SYK
● Live price
1.04%
Share price
$326.10
Annual div
$3.40
5Y div CAGR
46.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$43.3K
Annual income
$8,282.98
Full SYK calculator →
CEQP
CEQP
● Live price
9.27%
Share price
$28.26
Annual div
$2.62
5Y div CAGR
25.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$173.8K
Annual income
$54,802.53
Full CEQP calculator →

Portfolio growth — SYK vs CEQP

📍 CEQP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSYKCEQP
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SYK + CEQP cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SYK pays
CEQP pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SYK
Annual income on $10K today (after 15% tax)
$88.62/yr
After 10yr DRIP, annual income (after tax)
$7,040.53/yr
CEQP
Annual income on $10K today (after 15% tax)
$788.04/yr
After 10yr DRIP, annual income (after tax)
$46,582.15/yr
At 15% tax rate, CEQP beats the other by $39,541.62/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SYK + CEQP for your $10,000?

SYK: 50%CEQP: 50%
100% CEQP50/50100% SYK
Portfolio after 10yr
$108.6K
Annual income
$31,542.75/yr
Blended yield
29.05%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SYK right now

SYK
Analyst Ratings
1
Strong
35
Buy
14
Hold
Consensus: Buy
Price Target
$428.67
+31.5% upside vs current
Range: $390.00 — $469.00
Altman Z
4.0
Piotroski
5/9
CEQP
Analyst Ratings
8
Buy
9
Hold
1
Sell
Consensus: Hold
Price Target
$33.00
+16.8% upside vs current
Range: $28.00 — $35.00
Altman Z
1.3
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SYK buys
0
CEQP buys
12
PoliticianChamberTickerTypeAmountDate
Bill Hagerty🏛 Senate$CEQP▼ Sell$50,001 - $100,0002023-11-06
Mark Dr Green🏢 House$CEQP▼ Sell$250,001 - $500,0002020-12-10
Mark Dr Green🏢 House$CEQP▲ Buy$100,001 - $250,0002020-11-23
Mark Dr Green🏢 House$CEQP▼ Sell$100,001 - $250,0002020-10-22
Mark Dr Green🏢 House$CEQP▲ Buy$100,001 - $250,0002020-10-22
Mark Dr Green🏢 House$CEQP▲ Buy$15,001 - $50,0002020-10-05
Mark Dr Green🏢 House$CEQP▼ Sell$100,001 - $250,0002020-09-11
Mark Dr Green🏢 House$CEQP▲ Buy$15,001 - $50,0002020-08-28
Mark Dr Green🏢 House$CEQP▲ Buy$15,001 - $50,0002020-08-12
Mark Dr Green🏢 House$CEQP▲ Buy$15,001 - $50,0002020-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSYKCEQP
Forward yield1.04%9.27%
Annual dividend / share$3.40$2.62
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR46.2%25.6%
Portfolio after 10y$43.3K$173.8K
Annual income after 10y$8,282.98$54,802.53
Total dividends collected$21.0K$137.2K
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusBuyHold
Analyst price target$428.67$33.00

Year-by-year: SYK vs CEQP ($10,000, DRIP)

YearSYK PortfolioSYK Income/yrCEQP PortfolioCEQP Income/yrGap
1← crossover$10,852$152.43$11,864$1,164.44$1.0KCEQP
2$11,838$226.03$14,317$1,621.71$2.5KCEQP
3$13,004$336.89$17,616$2,297.06$4.6KCEQP
4$14,420$505.63$22,167$3,317.73$7.7KCEQP
5$16,195$766.09$28,619$4,900.54$12.4KCEQP
6$18,504$1,175.64$38,049$7,426.80$19.5KCEQP
7$21,635$1,835.40$52,303$11,590.39$30.7KCEQP
8$26,082$2,932.10$74,666$18,701.89$48.6KCEQP
9$32,737$4,829.68$111,232$31,339.23$78.5KCEQP
10$43,312$8,282.98$173,821$54,802.53$130.5KCEQP

SYK vs CEQP: Complete Analysis 2026

SYKHealthcare

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.

Full SYK Calculator →

CEQPStock

Crestwood Equity Partners LP develops, acquires, owns, controls, and operates assets and operations in the energy midstream sector in the United States. It operates through three segments: Gathering and Processing North; Gathering and Processing South; and Storage and Logistics. The Gathering and Processing North segment offers natural gas, crude oil, and produced water gathering, compression, treating, processing, and disposal services to producers in the Williston Basin and Powder River Basin. This segment owns and operates natural gas facilities with approximately 0.4 Bcf/d of gathering capacity and 0.5 Bcf/d of processing capacity; crude oil facilities with approximately 150,000 Bbls/d of gathering capacity and 266,000 Bbls of storage capacity; and produced water facilities with approximately 130,000 Bbls/d of gathering and disposal capacity. The Gathering and Processing South segment provides natural gas gathering, compression, treating, and processing; and produced water gathering and disposal services to producers in the Marcellus, Barnett, and Delaware basins. This segment owns and operates natural gas facilities with 2.5 Bcf/d of gathering capacity and 0.7 Bcf/d of processing capacity; and produced water facilities with approximately 75,000 Bbls/d of gathering and disposal capacity. The Storage and Logistics segment offers natural gas liquids, crude oil, and natural gas storage, terminal, marketing, and transportation, including rail, truck and pipeline services to producers, refiners, marketers, utilities, and other customers. Crestwood Equity GP LLC serves as the general partner of Crestwood Equity Partners LP. The company was formerly known as Inergy L.P. and changed its name to Crestwood Equity Partners LP in October 2013. Crestwood Equity Partners LP was incorporated in 2001 and is headquartered in Houston, Texas.

Full CEQP Calculator →
📬

Get this SYK vs CEQP comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SYK vs SCHDSYK vs JEPISYK vs OSYK vs KOSYK vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.